Phase I study of melphalan alone and melphalan plus whole body hyperthermia in dogs with malignant melanoma

References

• Alberts D. S., Chang S. Y., Chen H. S. G., Moon T. E., Evans T. E., Furner R. L., Himmelstein K., Gross J. F. Kinetics of intravenous melphalan. Clinical Pharmacology and Therapeutics 1979; 26: 73–80
   PubMed Web of Science ®Google Scholar
• Balch C. M., Soong S., Murad T. M., Smith J. W., Maddox W. A., Durant J. R. A multifactorial analysis of melanoma IV. Prognostic factors in 200 melanoma patients with distant metastasis. Journal of Clinical Oncology 1983; 1: 126–134
   PubMed Web of Science ®Google Scholar
• Bates D. A., Lheureux F., Fortier G. Enhancement of melphalan cytotoxicity at elevated temperatures in drug-sensitive and drug-resistant CHO cells. Proceedings, 10th Annual NAHG meeting, New Orleans, LA, 1990, 22, (abstr)
   Google Scholar
• Cox D. R., Snell E. J. Analysis of Binary Data, 23rd edn. Methuen, London 1989
   Google Scholar
• Dewhirst M. W., Sim D. A., Forsyth K., Grochowski K. J., Wilson S., Bicknell E. Local control and distant metastases in primary canine malignant melanomas treated with hyperthermia and/or hyperthermia. International Journal of Hyperthetmia 1985; 1: 219–234
   PubMedGoogle Scholar
• Dewhirst M. W., Sim D. A., Forsyth K., Grochowski K. J., Wilson S., Bicknell E. Local control and distant metastases in primary canine malignant melanomas treated with hyperthermia andlor hyperthermia. International Journal of Hyperthermia 1985; 1: 219–234
   PubMedGoogle Scholar
• Ghussen F., Nagel K., Groth W., Muller J. M., Stutzer H. A prospective randomized study of regional extremity perfusion in patients with malignant melanoma. Annals of Surgery 1984; 200: 764–768
   PubMed Web of Science ®Google Scholar
• Ghussen F., Kruger I., Groth W., Stutzer H. The role of regional hyperthermic cytostatic perfusion in the treatment of extremity melanoma. Cancer 1988; 61: 654–659
   PubMed Web of Science ®Google Scholar
• Harvey H. J., MacEwen E. G., Braun D., Patnaik A. K., Withrow J. J., Jongeward S. Prognostic criteria for dogs with oral melanoma. Journal of the American Vetzrinaty Medical Association 1981; 178: 580–582
   PubMed Web of Science ®Google Scholar
• Honess D. J., Bleehen N. M. Thermochemotherapy with cisplatinum, CCNU, BCNU, chloroambucil and melphalan on murine marrow and 2 tumours; therapeutic gain for melphalan only. British Journal of Radiology 1985a; 58: 63–68
   PubMedGoogle Scholar
• Honess D. J., Bleehen N. M. Potentiation of melphalan by systemic hyperthermia in mice: therapeutic gain for mouse lung microtumours. International Journal of Hyperthemia 1985b; 1: 57–68
   PubMedGoogle Scholar
• Honess D. J., Donaldson J., Workman P., Bleehen N. M. The effect of systemic hyperthermia on melphalan pharmacokinetics in mice. British Journal of Cancer 1985; 51: 77–84
   PubMed Web of Science ®Google Scholar
• Janoff K. A., Moseson D., Nohlgren J., Davenport C., Richards C., Fletcher W. S. The treatment of stage I melanoma of the extremities with regional hyperthermic isolation perfusion. Annals of Surgery 1982; 196: 316–319
   PubMedGoogle Scholar
• Johnson D. H., Presant C., Einhorn L. Cisplatin, vinblastine and bleomycin in the treatment of metastatic melanoma: a phase II study of the Southeastern Cancer Study Group. Cancer Treatment Reports 1985; 66: 1299–1302
   Google Scholar
• Kim J. H., Hahn E. W., Ahmed S. A. Combination hyperthermia and radiation therapy for malignant melanoma. Cancer 1982; 50: 478–482
   PubMed Web of Science ®Google Scholar
• Meyer R. E., Page R. L., Trall D. E., Dewhirst M. W., Vose D. L. Determination of continuous atracurium infusion rate in dogs undergoing whole body hyperthermia. Cancer Research 1986; 46: 5599–5601
   PubMed Web of Science ®Google Scholar
• Page R. L., Macy D. W., Thrall D. E., Dewhirst M. W., Allen S. L., Heidner G. L., Sim D. A., McGee M. W., Gillette E. L. Unexpected toxicity associated with use of body surface area for dosing, melphalan in the dog. Cancer Research 1988; 48: 288–290
   PubMed Web of Science ®Google Scholar
• Parsons P. G. Dependence on treatment time of melphalan resistance and DNA cross-linking in human melanoma cell lines. Cancer Research 1984; 44: 2773–2778
   PubMedGoogle Scholar
• Riviere J. E., Page R. L., Williams P. L., Rogers R. A., Chang S., Thrall D. E. Nonuniform cisplatin tissue distribution in dogs treated with whole body hyperthermia. Cancer Research 1990a; 50: 2075–2080
   PubMed Web of Science ®Google Scholar
• Rivitre I. E., Page R. L., Aucoin D. P., Rogers R. A., Williams P. L. Effect of hyperthermia on the in vitro and in vivo elimination of melphalan in dogs. International Sournal of Hyperthermia 1990b, (In press)
   Google Scholar
• Sarosy G., Leyland-Jones B., Soochan P., Cheson B. D. The systemic administration of intravenous melphalan. Journal of Clinical Oncology 1988; 6: 1768–1782
   PubMed Web of Science ®Google Scholar
• SAS Institute inc. SAS user's Guide: Statistics, Version 5 Edition. SAS Institute, Cary, NC 1985
   Google Scholar
• Stehim J. S., Giovanella B. C., De Ipolyi P. E., Muenz L. R., Anderson R. F. Results of hyperthermic perfusion for melanoma of the extremities. Surgery, Gynecology and Obsretrics 1975; 140: 339–348
   PubMedGoogle Scholar
• Todoroff R. F., Brodey R. S. Oral and pharyngeal neoplasia in the dog; a retrospective survey of 361 cases. Journal of the American Veterinary. Uedical Associution 1979; 175: 567–571
   PubMed Web of Science ®Google Scholar
• Thrale D. E., Page R. L., Dewhirst M. W., Meyer R. E., Hoopes P. J., Kornegay J. N. Temperature measurements in normal and tumor tissue in dogs undergoing whole body hyperthermia. Cancer Research 1986; 46: 6229–6235
   PubMedGoogle Scholar
• WHO. Handbook for Reporting Results of Cancer Treutment. World Health Organization, Geneva 1979
   Google Scholar